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Objective: To evaluate the efficacy and safety of monotherapy with adalimumab in patients with RA for
whom previous DMARD treatment has failed.
Methods: In a 26 week, double blind, placebo controlled, phase III trial, 544 patients with RA were
randomised to monotherapy with adalimumab 20 mg every other week, 20 mg weekly, 40 mg every
other week, 40 mg weekly, or placebo. The primary efficacy end point was >20% improvement in the
ACR core criteria (ACR20 response). Secondary efficacy end points included ACR50, ACR70, EULAR
responses, and the Disability Index of the Health Assessment Questionnaire (HAQ DI).
Results: After 26 weeks, patients treated with adalimumab 20 mg every other week, 20 mg weekly,
40 mg every other week, and 40 mg weekly had significantly better response rates than those treated with
placebo: ACR20 (35.8%, 39.3%, 46.0%, 53.4%, respectively v 19.1%; p(0.01); ACR50 (18.9%, 20.5%,
22.1%, 35.0% v 8.2%; p(0.05); ACR70 (8.5%, 9.8%, 12.4%, 18.4% v 1.8%; p(0.05). Moderate EULAR
response rates were significantly greater with adalimumab than with placebo (41.5%, 48.2%, 55.8%,
63.1% v 26.4%; p(0.05). Patients treated with adalimumab achieved better improvements in mean HAQ
DI than those receiving placebo (20.29, 20.39, 20.38, 20.49 v 20.07; p(0.01). No significant
differences were found between adalimumab and placebo treated patients for serious adverse events,
serious infections, or malignancies. Injection site reaction occurred in 10.6% and 0.9% of adalimumab and
placebo treated patients, respectively (p(0.05).
Conclusion: Among patients with RA for whom previous DMARD treatment had failed, adalimumab
monotherapy achieved significant, rapid, and sustained improvements in disease activity and improved
physical function and was safe and well tolerated.
R
heumatoid arthritis (RA) is an idiopathic autoimmune
disorder characterised by symmetrical synovitis that
may lead to progressive joint destruction and disability.1
Traditional disease modifying antirheumatic drugs
(DMARDs), among which methotrexate (MTX) is the most
frequently used, have been shown to improve signs and
symptoms of RA, in addition to reducing or preventing joint
destruction.2 Despite traditional DMARD treatment, many
patients continue to experience disease activity. For such
patients, biological DMARDs, such as tumour necrosis factor
(TNF) antagonists, are recommended when an adequate trial
of a traditional DMARD fails to elicit a response.3
Accumulating evidence indicates that TNF antagonists can
be used either in combination with pre-existing DMARD
treatment or, when appropriate, as replacement monother-
apy.3 Three TNF antagonists have been approved for the
treatment of RA: infliximab (a chimeric, anti-TNF mono-
clonal antibody),4 etanercept (a human, TNF receptor-Fc
fusion protein),5 and adalimumab (a human, anti-TNF
monoclonal antibody).6
Adalimumab (Humira; Abbott Laboratories) was geneti-
cally engineered using phage display technology and is
structurally and functionally analogous to naturally occurring
human immunoglobulin G1 (IgG1).7 This monoclonal anti-
body demonstrates a high specificity and affinity for TNF
(Kd = 6610
210 M) but not other cytokines, such as lympho-
toxin (TNFb),7 and has a terminal half life comparable to that
of human IgG1 (about 2 weeks).8 9 The mechanism of action
for adalimumab involves blocking the interaction of TNF
with the p55 and p75 TNF cell surface receptors.7 Clinical
trials have shown that adalimumab is effective in controlling
the signs and symptoms of RA6 8–11 and inhibiting the long
term progression of joint destruction.8
Until the introduction of TNF antagonists, patients who
did not respond to traditional DMARDs had few therapeutic
options. Achieving success with TNF antagonist monotherapy
in such patients would be a rigorous test of efficacy. The
objective of this double blind, placebo controlled, phase III
study was to evaluate the efficacy and safety of adalimumab
monotherapy given as subcutaneous (sc) injections in
patients with active RA for whom treatment with at least
one DMARD had failed.
METHODS
Patients
Patients aged 18 years or older were recruited from 52 centres
in Europe, Canada, and Australia. Eligible patients met the
diagnostic criteria for RA established by the American College
of Rheumatology (ACR),12 13 treatment with at least one
DMARD had previously failed, and they had active disease
Abbreviations: ACR, American College of Rheumatology; ANA,
antinuclear antibody; CRP, C reactive protein; DAS, disease activity
score; DMARDs, disease modifying antirheumatic drugs; ESR,
erythrocyte sedimentation rate; EULAR, European League Against
Rheumatism; HAQ DI, Disability Index of the Health Assessment
Questionnaire; MTX, methotrexate; NSAIDs, non-steroidal anti-




defined as >12 tender joints based on a 68 joint assessment,
>10 swollen joints based on a 66 joint evaluation, and either
an erythrocyte sedimentation rate (ESR) >28 mm/1st h or a
serum C reactive protein (CRP) concentration >20 mg/l. A
negative pregnancy test and the use of a reliable contra-
ceptive method were mandatory in women of childbearing
potential.
Exclusion criteria included joint surgery within 2 months
before screening or infection requiring admission to hospital
or treatment with intravenous (iv) antibiotics within
1 month before screening. Patients were excluded if they
had received treatment with either an intra-articular or
intramuscular corticosteroid within 1 month before the study
or an investigational small molecule drug or biological agent
within 2 months or 6 months before screening, respectively.
Patients with impaired renal or hepatic function, or a history
of tuberculosis as shown by radiographs, were excluded from
the study. All patients were required to give written informed
consent.
Protocol
This study was a 26 week, double blind, placebo controlled,
phase III randomised trial of adalimumab monotherapy
performed between January 2000 and June 2001. Ethics
committees (in Europe and Australia) and research commit-
tees (in Canada) approved the trial at their respective study
sites. After screening and baseline assessments, study visits
were conducted every other week during the first month,
monthly thereafter, and at week 26. Patients who dropped
out were followed up at 1, 2, 3, and 6 months after treatment.
Patients were randomised in a blinded fashion during the
baseline visit in blocks of five patients each to one of the
following five treatment arms: adalimumab 20 mg given
subcutaneously (sc) every other week (with placebo injected
on the alternate week), adalimumab 20 mg sc weekly,
adalimumab 40 mg sc every other week (with placebo
injected on the alternate week), adalimumab 40 mg sc
weekly, or placebo weekly. Treatment allocation was done
in a double blind fashion by a computer generated
randomisation list, and blinding was achieved by the
packaging procedure for the study drug. The study drug
was provided in ready to use unit dose vials of 1.6 ml
injectable solution containing adalimumab 20 mg, adalimu-
mab 40 mg, or placebo. Patients were instructed on self
injection techniques.
Patients taking traditional DMARDs at the time of
recruitment were required to undergo a 4 week washout
period before the initial injection of the study drug. Use of
non-steroidal anti-inflammatory drugs (NSAIDs) and oral
corticosteroids before the study was allowed at stable pre-
enrolment doses and routes of administration, with a daily
dose limit equivalent to prednisolone 10 mg. Analgesics such
as propoxyphene, codeine, or aspirin were permitted, but not
within 12 hours of study visits. Adalimumab or placebo
treated patients who had increased inflammatory synovitis or
,10% improvement in tender and swollen joint counts after
at least 8 weeks of treatment could have elected to enter a
rescue arm, during which the study drug could have been
discontinued and doses of NSAIDs or corticosteroids could
have been increased. In addition, other DMARDs could have
been initiated as rescue treatment at the investigator’s
discretion. Patients entering the rescue arm as well as those
completing the 26 week trial could subsequently have elected
to enter an open label adalimumab continuation study.
Efficacy assessment
The primary efficacy end point was the rate of ACR20
response (>20% improvement in the ACR core criteria).
Secondary efficacy end points included the ACR50 and
ACR70 response rates and improvements in ACR core
components (patient global assessment of disease activity,
physician global assessment of disease activity, patient
assessment of pain, the Disability Index of the Health
Assessment Questionnaire (HAQ DI), and serum levels of
CRP).13 14 Additionally, clinical response was measured by
changes in the disease activity score 28 (DAS28), a composite
score (scale 2–10) defined by criteria established by the
European League Against Rheumatism (EULAR).15–20 No
EULAR response was defined as a decrease in DAS28 of
(0.6 or a decrease .0.6 but (1.2 with an attained DAS28
of .5.1. A good EULAR response was defined as a decrease
in DAS28 of .1.2 and an attained DAS28 of (3.2.
Remaining patients were classified as moderate EULAR
responders.
Safety assessment
Safety was evaluated based on adverse event data (for
example, type, severity, time of occurrence, time to resolu-
tion) provided by physical examinations and patient self
reporting. Safety assessments were conducted at screening,
baseline, and every study and follow up assessment. Patients
were routinely tested for the presence of antibodies against
adalimumab with a sensitive double antigen, enzyme linked
immunosorbent assay (ELISA). A positive signal for anti-
bodies against adalimumab was defined as a titre .20 ng/ml
with ,50% suppression when 10% human serum was added
to a sample. Patients were regularly monitored for anti-
nuclear antibodies (ANAs) and, when ANA titres were raised
from baseline, for anti-double-stranded DNA (anti-dsDNA)
antibodies. Positive ANAs were defined as titres >1/80, and
positive anti-dsDNA levels as >25 kU/l.
Statistical analysis
A sample size of 90 patients in each treatment group was
required to detect a difference of 30% in ACR20 response
rates between an adalimumab dose group and placebo (with
a predicted ACR20 response rate of 20% for placebo and with
statistical power of at least 95% probability). The overall level
of significance was set at p = 0.05. The study was not
powered to detect differences between individual adalimu-
mab groups. To account for the few patients who might not
be evaluable for any reason, the sample size was set at 100
patients in each treatment group.
Demographic and baseline characteristics were sum-
marised by descriptive statistics and compared between
treatment groups to assess baseline homogeneity using one
way analysis of variance or the Kruskal-Wallis test for
continuous variables and the Cochran-Mantel-Haenszel test
or Pearson’s x2 test for discrete variables.
An intention to treat analysis was performed that included
patients who were randomised and who received at least one
injection of the randomised study drug. The response rates
for the primary efficacy end point (ACR20 at week 26) for
each adalimumab group were compared with that of placebo
using a two sided Pearson’s x2 test. The Bonferroni-Holm
procedure was applied to account for multiplicity of testing.
Improvement in RA (that is, fulfilment of ACR20 response
criteria) was defined as change from baseline. Patients not
completing the trial (that is, who were withdrawn or required
rescue) despite fulfilling ACR criteria were considered non-
responders upon withdrawing or entering rescue.
Improvements in the seven ACR core components were
compared between adalimumab and placebo treated patients
using an analysis of covariance model, with baseline values
as covariates. No a correction for multiple testing was applied
to secondary efficacy variables. Comparisons of the active
treatment groups with placebo were performed on the basis
of the adjusted means resulting from these models.
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RESULTS
Demographic characteristics and baseline disease
activity
There were no statistically significant differences in the
demographic characteristics and baseline disease activity
between the treatment groups (table 1). Most patients were
female (77.4%), and the overall mean age was 53 years. At
baseline, these patients had longstanding, severe RA and
previous DMARD treatment had failed. Upon entering the
study, patients had experienced RA for an overall average of
11 years. Tender and swollen joint counts averaged 34.4 and
19.8, respectively; the mean score for the HAQ DI was 1.9; the
mean DAS28 was 7.07; and 81.6% of patients tested positive
for rheumatoid factor. Additionally, the mean CRP concen-
tration was 51.7 mg/l, and the mean ESR was 53.5 mm/1st h.
An average of 3.7 DMARDs had been unsuccessfully used in
the treatment of patients. The majority of patients (71.5%)
had been unsuccessfully treated with three or more
DMARDs. The most common previously used DMARDs
included MTX, sulfasalazine, antimalarial drugs, and par-
enteral gold, which had failed in 90%, 60%, 59%, and 52% of
randomised patients, respectively.
Patient disposition
A total of 827 patients with RA were screened. Of those, 544
patients met entry criteria and were randomly allocated to
five treatment groups: 106 patients (19.5%) to adalimumab
20 mg every other week, 112 (20.6%) to adalimumab 20 mg
weekly, 113 (20.8%) to adalimumab 40 mg every other week,
103 (18.9%) to adalimumab 40 mg weekly, and 110 (20.2%)
to placebo (fig 1). Withdrawals occurred in 118/434 (27.2%)




ACR20, ACR50, and ACR70 response rates (observed values)
for all dosing regimens of adalimumab were significantly
better than with placebo at week 26 (table 2) and at most of
the other evaluation points (fig 2) (p(0.05). ACR20 response
rates at week 26, the primary efficacy end point, were 35.8%,
39.3%, 46.0%, and 53.4% with adalimumab 20 mg every
other week, 20 mg weekly, 40 mg every other week, and
40 mg weekly, respectively, versus 19.1% with placebo
(p(0.01). ACR70 response rates for adalimumab 40 mg
every other week were significantly better at all evaluation
points and for adalimumab 40 mg weekly at most evaluation
points compared with placebo (p(0.05) (fig 2). The sample
size did not allow statistically meaningful comparisons
between the individual adalimumab regimens. For all
adalimumab treatment groups combined, there was no
significant difference in ACR20 response rates at week 26
between patients with or without concomitant corticosteroid
treatment (44.5% (133/299) v 41.5% (56/135), respectively),
suggesting that concomitant corticosteroid treatment did not
affect the response to adalimumab.
EULAR response
Consistent with ACR responses, at least moderate (both
moderate and good) EULAR response rates (observed values)
Table 1 Patient demographic and baseline clinical characteristics*
Parameter
Adalimumab sc
Placebo (n = 110)
20 mg 40 mg
Every other week
(n = 106) Weekly (n = 112)
Every other week
(n = 113) Weekly (n = 103)
Age (years) 53.1 (12.2) 54.4 (11.8) 52.7 (13.3) 51.8 (11.8) 53.5 (13.2)
Female, No (%) 84 (79.2) 81 (72.3) 90 (79.6) 81 (78.6) 85 (77.3)
RA duration (years) 9.3 (6.4) 11.3 (8.6) 10.6 (6.9) 11.9 (8.8) 11.6 (9.3)
Previous treatments
Number of traditional DMARDs 3.7 (1.9) 3.6 (1.7) 3.8 (1.8) 3.8 (2.0) 3.6 (1.8)
Treatment failures, No (%)
>3 Traditional DMARDs 75 (70.8) 82 (73.2) 84 (74.3) 72 (69.9) 76 (69.1)
MTX 94 (88.7) 105 (93.8) 105 (92.9) 90 (87.4) 95 (86.4)
Concomitant treatments, No (%)
NSAIDs 86 (81.1) 84 (75.0) 93 (82.3) 79 (76.7) 92 (83.6)
Corticosteroids 74 (69.8) 76 (67.8) 77 (68.1) 84 (81.6) 74 (67.3)
Disease activity
Tender joint count (range 0–68) 33.9 (14.4) 35.3 (14.9) 33.7 (15.9) 33.8 (14.0) 35.5 (14.2)
Swollen joint count (range 0–66) 19.6 (8.7) 19.8 (9.7) 20.5 (10.6) 19.3 (8.8) 19.8 (9.3)
Patient assessment of pain (scale 0–100)` 73.8 (18.2) 71.1 (21.0) 70.1 (19.9) 71.2 (19.1) 70.2 (18.1)
Patient global assessment of disease activity (scale 0–100)175.1 (18.2) 74.0 (20.1) 72.5 (19.3) 74.2 (18.7) 71.8 (19.9)
Physician global assessment of disease activity
(scale 0–100)1
69.6 (17.6) 68.1 (17.5) 67.0 (16.7) 67.7 (17.0) 68.5 (18.2)
Health Assessment Questionnaire Disability Index
(scale 0–3)
1.88 (0.60) 1.88 (0.63) 1.83 (0.59) 1.84 (0.57) 1.88 (0.64)
C reactive protein (mg/l) 52.4 (52.1) 47.2 (37.6) 52.6 (37.4) 49.3 (40.4) 57.0 (49.0)
Erythrocyte sedimentation rate (mm/1st h) 52.8 (27.9) 51.5 (24.8) 55.8 (27.0) 51.1 (25.0) 56.1 (28.0)
Rheumatoid factor positive, No (%) 85 (80.2) 94 (83.9) 90 (79.6) 85 (82.5) 90 (81.8)
DAS28 (scale 2–10)** 7.08 (0.92) 7.09 (0.86) 7.07 (0.86) 7.02 (0.81) 7.09 (0.87)
*No statistically significant differences were noted in any demographic or baseline characteristic between the placebo group and the adalimumab dose groups and
dose regimens (Kruskal-Wallis test for continuous variables and Pearson’s x2 test for discrete variables); results are shown as mean (SD) unless otherwise
indicated; `0, no pain; 100, severe pain; 10, no disease activity; 100, extreme disease activity; 0, no difficulty; 3, unable to perform activity; **higher score
indicates greater disease activity.
sc, subcutaneous; RA, rheumatoid arthritis; DMARDs, disease modifying antirheumatic drugs; MTX, methotrexate; NSAIDs, non-steroidal anti-inflammatory drugs;
DAS, disease activity score.
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for all adalimumab regimens were significantly better than
for placebo at week 26 (table 2) and at all other evaluation
points (fig 3) (p(0.05). At least moderate EULAR response
rates were 41.5%, 48.2%, 55.8%, and 63.1% with adalimumab
20 mg every other week, 20 mg weekly, 40 mg every other
week, and 40 mg weekly, respectively, compared with 26.4%
with placebo (p(0.05). At week 26, significantly more
patients treated with adalimumab 40 mg weekly versus
those treated with placebo achieved a good EULAR response
(p(0.01) (table 2).
Onset and maintenance of ACR and EULAR
responses
Significant improvements in ACR20, ACR50, and at least
moderate EULAR response rates with each adalimumab
regimen compared with placebo (p(0.05) were evident as
Figure 1 Patient disposition.
Table 2 American College of Rheumatology response (ACR20, ACR50, and ACR70) and European League Against
Rheumatism (EULAR) response (at least moderate and good) at weeks 2 and 26 (observed values)
Response
Adalimumab sc
Placebo (n = 110)
20 mg 40 mg
Every other week
(n = 106) Weekly (n = 112)
Every other week
(n = 113) Weekly (n = 103)
ACR20
Week 2 40 (37.7)` 43 (38.4)` 40 (35.4)` 34 (33.0)` 8 (7.3)
Week 26 38 (35.8) 44 (39.3)` 52 (46.0)` 55 (53.4)` 21 (19.1)
ACR50
Week 2 5 (4.7)* 7 (6.3) 11 (9.7)` 11 (10.7)` 0 (0.0)
Week 26 20 (18.9)* 23 (20.5) 25 (22.1) 36 (35.0)` 9 (8.2)
ACR70
Week 2 1 (0.9) 0 (0.0) 4 (3.5)* 2 (1.9) 0 (0.0)
Week 26 9 (8.5)* 11 (9.8)* 14 (12.4) 19 (18.4)` 2 (1.8)
EULAR: at least moderate 1
Week 2 51 (48.1)` 54 (48.2)` 57 (50.4)` 50 (48.5)` 16 (14.5)
Week 26 44 (41.5)* 54 (48.2)` 63 (55.8)` 65 (63.1)` 29 (26.4)
EULAR: good1
Week 2 2 (1.9) 1 (0.9) 4 (3.5)* 1 (1.0) 0 (0.0)
Week 26 7 (6.6) 11 (9.8) 10 (8.8) 14 (13.6) 4 (3.6)
Results are shown as No (%).
Comparison v placebo (Pearson’s x2 test): *p(0.05; p(0.01; `p(0.001.
1No EULAR response was defined as a decrease in DAS28 of (0.6 or a decrease .0.6 but (1.2 with an attained DAS28 of.5.1. A good EULAR response was
defined as a decrease in DAS28 of .1.2 and an attained DAS28 of (3.2. Remaining patients were classified as EULAR moderate responders.
sc, subcutaneous; DAS, disease activity score.
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early as week 2, the first evaluation point (table 2; figs 2 and
3). At week 2, ACR20 response rates were 37.7%, 38.4%,
35.4%, and 33.0% with respective adalimumab dosages
compared with 7.3% with placebo (p(0.001). Significant
improvements versus placebo in ACR70 and good EULAR
response rates were evident at week 2 with adalimumab
40 mg every other week (p(0.05) (table 2; figs 2 and 3).
Overall, in adalimumab treated patients, ACR20 and at least
moderate EULAR response rates peaked at approximately
week 12 and remained at that level thereafter, whereas
ACR50, ACR70, and good EULAR response rates continued to
rise (figs 2 and 3).
ACR core component and DAS28 responses
At week 26, ACR core component and DAS28 response rates
were significantly greater with adalimumab 40 mg every
other week and weekly than with placebo (p(0.001)
(table 3). Adalimumab 20 mg every other week and weekly
reached significance for most of these end points (p(0.05)
(table 3). After 26 weeks of treatment, the tender joint count
decreased by 35.5%, 42.4%, 37.4%, and 48.0% with respective
adalimumab doses in contrast with a 9.5% decrease
with placebo. The swollen joint count decreased by
28.0%, 34.6%, 37.0%, and 40.1% with respective adalimumab
doses compared with a 7.4% decrease with placebo. HAQ DI
decreased by 14.7%, 18.5%, 21.3%, and 28.7% with respective
adalimumab doses, while increasing 1.8% with placebo.
Patients treated with respective adalimumab doses achieved
significantly better improvements in mean HAQ DI (20.29,
20.39, 20.38, and 20.49) versus placebo (20.07) (p(0.01).
Safety
Adalimumab was well tolerated, and most adverse events
were mild or moderately severe. Significantly more adalimu-
mab treated patients (429/434; 98.8%) than placebo treated
patients (105/110; 95.5%) reported at least one adverse event
(p(0.05). However, the mean duration of exposure to study
drug was greater with adalimumab (162.0 days) than with
placebo (133.9 days). To adjust for the higher rate of
withdrawals and shorter amount of treatment time in the
placebo group, adverse events were also analysed by the total
Figure 2 Percentages of patients treated with adalimumab or placebo
who had at least 20%, 50%, and 70% improvements in ACR response
criteria (ACR20, ACR50, ACR70; observed values). Comparison versus
placebo (Pearson’s x2 test): *p(0.05; p(0.01; `p(0.001.
Figure 3 Percentages of patients treated with adalimumab or placebo
who had improvements in the European League Against Rheumatism
(EULAR) response criteria (observed values). Comparison versus placebo
(Pearson’s x2 test): *p(0.05; p(0.01; `p(0.001.
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number of patients experiencing a particular adverse event
per total years of treatment (patients/patient-year). Based on
this analysis, the occurrence of adverse events was compar-
able between adalimumab treated patients (2.23 patients/
patient-year) and placebo treated patients (2.60 patients/
patient-year).
Among the most common adverse events (>10% in any
treatment group), headache, rash (at a site other than the
injection site), injection site reaction (localised erythema,
itching, haemorrhage, pain, or swelling), and pruritus
occurred significantly more often in adalimumab treated
patients than placebo treated patients (p(0.05) (table 4).
Injection site reactions occurred in 10.6% of adalimumab
treated patients and 0.9% of placebo treated patients
(p(0.05).
There was no statistically significant difference in the rates
of serious adverse events between adalimumab treated
patients (53/434; 12.2%) and placebo treated patients (16/
110; 14.5%). Furthermore, there was no dose-response effect
with adalimumab for serious adverse events, which were
reported in 10.4%, 16.1%, 11.5%, and 10.7% of patients
treated with adalimumab 20 mg every other week, 20 mg
weekly, 40 mg every other week, and 40 mg weekly,
respectively. The rates of serious infections were statistically
similar between adalimumab treated patients (10/434; 2.3%)
and placebo treated patients (0/110; 0%). All cases of serious
Table 3 Response for secondary outcome end points at week 26
Parameter*
Adalimumab sc
Placebo (n = 110)
20 mg 40 mg
Every other week
(n = 106) Weekly (n = 112)
Every other week
(n = 113) Weekly (n = 103)
Tender joint count (range 0–68)
Mean baseline value 33.7 (14.3) 35.3 (14.9) 33.9 (15.8) 33.8 (14.0) 35.5 (14.2)
Absolute change 211.2 (14.9) 214.9 (15.7) 213.6 (18.7) 217.1 (15.5) 26.6 (16.6)
Percentage change 235.5 242.4 237.4 248.0 29.5
p Value` (0.01 (0.001 (0.001 (0.001
Swollen joint count (range 0–66)
Mean baseline value 19.4 (8.6) 19.8 (9.7) 20.5 (10.6) 19.4 (8.8) 19.8 (9.3)
Absolute change 25.7 (10.5) 27.2 (11.0) 28.5 (10.6) 28.3 (10.8) 22.4 (9.5)
Percentage change 228.0 234.6 237.0 240.1 27.4
p Value` (0.01 (0.001 (0.001 (0.001
Patient assessment of pain (scale 0–100)1
Mean baseline value 73.8 (18.2) 71.1 (21.0) 70.3 (19.9) 71.4 (19.1) 70.2 (18.1)
Absolute change 220.1 (30.3) 225.2 (30.8) 227.6 (31.1) 232.0 (31.3) 211.0 (26.7)
Percentage change 226.4 233.4 237.7 242.4 211.4
p Value` – (0.001 (0.001 (0.001
Patient global assessment of disease activity (scale 0–100)
Mean baseline value 75.1 (18.2) 74.0 (20.1) 72.6 (19.3) 74.4 (18.6) 71.8 (19.9)
Absolute change 219.5 (29.9) 226.5 (31.6) 227.9 (30.5) 235.0 (31.5) 210.6 (27.8)
Percentage change 225.1 233.9 238.9 244.1 27.9
p Value` – (0.001 (0.001 (0.001
Physician global assessment of disease activity (scale 0–100) 
Mean baseline value 69.6 (17.6) 68.1 (17.5) 67.3 (16.6) 68.0 (16.8) 68.5 (18.2)
Absolute change 220.5 (27.0) 226.4 (28.8) 227.3 (28.8) 232.5 (27.3) 210.9 (25.4)
Percentage change 229.1 238.9 238.8 245.5 212.9
p Value` (0.001 (0.001 (0.001 (0.001
Health Assessment Questionnaire Disability Index (scale 0–3)**
Mean baseline value 1.88 (0.60) 1.88 (0.63) 1.83 (0.59) 1.83 (0.57) 1.88 (0.64)
Absolute change 20.29 (0.63) 20.39 (0.62) 20.38 (0.60) 20.49 (0.54) 20.07 (0.49)
Percentage change 214.7 218.5 221.3 228.7 +1.8
p Value` (0.01 (0.001 (0.001 (0.001
C reactive protein (mg/l)
Median baseline value 37.6 37.6 46.2 41.9 39.2
Absolute change 24.3 210.7 219.5 216.7 +3
Percentage change 218.5 238.8 242.8 254.4 +0.4
p Value` – (0.01 (0.001 (0.001
Erythrocyte sedimentation rate (mm/1st h)
Median baseline value 45.0 48.0 54.0 49.0 50.5
Absolute change 22.5 25.5 212.0 212.0 22.0
Percentage change 25.9 212.7 228.8 229.4 24.4
p Value` – (0.05 (0.001 (0.001
DAS28 (scale 2–10)
Mean baseline value 7.1 (0.9) 7.1 (0.9) 7.1 (0.8) 7.0 (0.8) 7.1 (0.9)
Absolute change 21.3 (1.6) 21.6 (1.7) 21.7 (1.6) 22.0 (1.6) 20.7 (1.3)
Percentage change 218.2 223.3 223.8 228.4 29.1
p Value` (0.01 (0.001 (0.001 (0.001
*Results shown as mean value (SD) unless stated otherwise; a negative absolute or percentage change indicates an improvement in that ACR response criterion;
last observation carried forward; `p value for adalimumab absolute change versus placebo absolute change (by analysis of covariance; for C reactive protein and
erythrocyte sedimentation rate, Wilcoxon and Mann-Whitney test); 10, no pain; 100, severe pain; 0, no disease activity; 100, extreme disease activity; **0, no
difficulty; 3, unable to perform activity; higher score indicates greater disease activity.
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infection were treated and resolved during the course of the
trial. There were no cases of primary or reactivation
tuberculosis among adalimumab treated patients during the
study. Malignancies occurred at statistically similar rates
with adalimumab (4/434; 0.9%) and placebo (1/110; 0.9%).
Four deaths occurred during the study, including three pati-
ents treated with adalimumab (metastatic adenocarcinoma,
cholangiocarcinoma, and myocardial infarction) and one
with placebo (complications of a bowel obstruction), all of
which were judged either unrelated or unlikely to be related
to the study drug.
Conversion from ANA negative at baseline to positive at
week 26 occurred in 12.2% (53/434) of adalimumab treated
patients and 5.5% (6/110) of placebo treated patients,
whereas 10.4% (45/434) of adalimumab treated patients
and 8.2% (9/110) of placebo treated patients converted from
ANA positive to negative.
Over the course of the study, 12% of adalimumab treated
patients tested positive for antibodies against adalimumab;
however, there were no differences in the pattern or
frequency of adverse events between patients with or without
these antibodies. Among all adalimumab treatment groups
combined, the ACR20 response rate at week 26 was
numerically lower for patients who were positive for
adalimumab antibodies than for those who were negative,
but among patients treated with the recommended dose21 of
40 mg every other week, there was no statistically significant
difference in ACR20 response rates at week 26 between both
groups.
DISCUSSION
In this study, adalimumab, the first human anti-TNF
monoclonal antibody to be investigated for the treatment of
RA, was found to be effective in reducing disease activity and
in improving functional capacity in patients with severe,
longstanding RA for whom previous DMARD treatment had
failed. Despite disease severity in these patients, adalimumab
monotherapy achieved significant, rapid responses, which
were evident as early as week 2, the first evaluation, and were
sustained or improved throughout the study.
Significant numbers of patients in all four adalimumab
groups had improved clinically, even with the most stringent
response criteria (ACR70 response). Although the study was
not powered to detect statistical differences among the
adalimumab treatment groups, there appeared to be a trend
towards better efficacy with the adalimumab 40 mg dose
groups. Overall, the weekly 40 mg dose seemed to offer
benefits over the every other week 40 mg dose, although such
differences were less pronounced than those between the 20
and 40 mg doses. Therefore, the clinical implications drawn
from these data are in agreement with the current dosing
recommendations (that is, the recommended dose of 40 mg
every other week, with some patients not taking concomitant
MTX deriving additional benefit from increasing the dosing
frequency to 40 mg every week21).
All regimens of adalimumab significantly improved most
individual measures of disease activity and, based on
outcome values suggested by Goldsmith et al,22 produced
clinically important changes in tender and swollen joint
counts, HAQ DI, patient and physician global assessments,
and patient assessment of pain. Improvements in HAQ DI
suggest that adalimumab treatment has a positive impact on
patients’ ability to perform physical activities necessary for
daily living. Also of note, significant (p(0.001) improve-
ments in the acute phase reactant CRP were achieved with
the 40 mg dose regimens. These results are encouraging in
light of recent reports linking raised CRP levels to progressive
joint damage and impaired functional capacity in late RA.23 24
The results of this study show that it is possible to
successfully treat people with severely active RA for whom
many treatment regimens have failed. Adalimumab mono-
therapy provided rapid, sustained improvement in the signs
and symptoms of this disease, despite the fact that this study
enrolled one of the most severely afflicted patient groups ever
studied in RA, as shown by eligibility analyses of other trials.
For example, an eligibility analysis of a phase III trial of
infliximab,25 in which the baseline HAQ scores ranged from
1.5 to 1.8 (versus 1.9 in our trial), found that only a small
percentage (,5%) of patients with long term RA, as defined
by ACR criteria, met the inclusion criteria for disease
severity.26 Moreover, in a phase II study of etanercept, in
which the baseline HAQ scores ranged from 1.6 to 1.7, ACR
responses at 6 months for patients receiving active treatment
were comparable to those for patients receiving adalimumab
in this trial (for example, ACR70 responses of up to 18.4% for
adalimumab v 15% for etanercept),27 thus signifying the
degree of clinical success demonstrated in our study with
such a patient group.
The doses of adalimumab (20 and 40 mg) used in this
study were selected based on the findings of a phase II, dose
ranging monotherapy study with weekly sc injections of
adalimumab 20, 40, and 80 mg in patients non-responsive to
traditional DMARD treatment.28 That study showed that the
efficacy provided by the 40 mg weekly dose was similar to
Table 4 Most frequently reported adverse events*
Adverse event
Adalimumab sc
All regimens (n = 434) Placebo (n = 110)









Clinical flare reaction 25 (23.6) 22 (19.6) 18 (15.9) 16 (15.5) 81 (18.7) 24 (21.8)
Rhinitis 11 (10.4) 21 (18.8) 21 (18.6) 22 (21.4) 75 (17.3) 12 (10.9)
Headache 22 (20.8) 20 (17.9) 24 (21.2) 21 (20.4) 87 (20.0) 11 (10.0)
Rash 15 (14.2) 18 (16.1) 23 (20.4) 12 (11.7) 68 (15.7) 6 (5.5)
Injection site reaction 5 (4.7) 13 (11.6) 11 (9.7) 17 (16.5) 46 (10.6) 1 (0.9)
Sore throat 14 (13.2) 4 (3.6) 11 (9.7) 5 (4.9) 34 (7.8) 7 (6.4)
Back pain 9 (8.5) 4 (3.6) 7 (6.2) 13 (12.6) 33 (7.6) 4 (3.6)
Gastrointestinal pain 13 (12.3) 5 (4.5) 5 (4.4) 3 (2.9) 26 (6.0) 5 (4.5)
Pruritus 11 (10.4) 8 (7.1) 13 (11.5) 9 (8.7) 41 (9.4) 1 (0.9)
Nausea 8 (7.5) 8 (7.1) 9 (8.0) 11 (10.7) 36 (8.3) 8 (7.3)
Diarrhoa 6 (5.7) 7 (6.3) 8 (7.1) 3 (2.9) 24 (5.5) 11 (10.0)
Results are shown as No (%)
*Occurring in >10% of patients in any treatment group; p(0.05 v placebo.
sc, subcutaneous.
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that provided by the 80 mg weekly dose. Expanding upon the
results of that study, our investigation included the recom-
mended adalimumab dose (40 mg every other week).
In this 26 week trial, all adalimumab doses and regimens
were well tolerated. Overall, adverse events were mild or
moderately severe. Among the most common adverse events,
headache, rash, injection site reaction, and pruritus occurred
significantly more often in adalimumab treated patients than
in placebo treated patients (p(0.05). The incidence of
injection site reaction, a commonly occurring adverse event
with sc agents, was relatively low (10.6%). Across all pivotal
trials of adalimumab with durations between 24 and
52 weeks, a 20.3% incidence of injection site reaction has
been reported.29 Injection site reactions related to treatment
have been reported with other sc RA drugs (incidence rates of
37% and 70% for etanercept and anakinra, respectively).30 31
There were no statistically significant differences between
adalimumab treated patients and placebo treated patients in
the rates of serious adverse events (12.2% v 14.5%, respec-
tively). Moreover, a dose-response effect with adalimumab
for serious adverse events was not evident. There was no
statistically significant difference between adalimumab and
placebo treated patients in the rates of serious infection (2.3%
v 0%, respectively), and no cases of primary or reactivation
tuberculosis were seen during the study among adalimumab
treated patients. Despite such results, it should be noted that
patients treated with TNF antagonists are at increased risk of
developing serious infections, including tuberculosis.32 33
Patients should be screened for latent tuberculosis infection
before starting treatment with a TNF antagonist.
In conclusion, among patients with RA for whom previous
DMARD treatment had failed, adalimumab monotherapy
achieved significant, rapid, and sustained improvements in
disease activity and improved physical function while being
safe and well tolerated. Responses were higher overall for the
adalimumab 40 mg dose regimens. Our findings suggest that
adalimumab monotherapy is a therapeutic option for patients
with longstanding, severe RA when previous DMARD
treatment has failed.
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